1 Section of Pulmonary and Critical Care Medicine, Department of Medicine, and 3 Committees on Clinical Pharmacology and Cell Physiology, Division of the Biological Sciences, and 2 Department of Pathology, University of Chicago, Chicago, Illinois 60637
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We assessed the effect of anti-CD3-stimulated secretion
of cultured human Th1- and Th2-like cells on leukotriene C4
(LTC4) secretion in isolated human eosinophils. T helper
(Th) cell subsets were generated from human naive CD4+ T
cells cocultured with irradiated human transformed B cells and either
recombinant human interleukin (rhIL)-1 plus rhIL-6 plus rhIL-12 for
Th1-like cells or rhIL-1
plus rhIL-6 plus rhIL-4 for Th2-like cells.
Coincubation of eosinophils with 1:5 dilution of Th2-supernatant (Sup)
caused an increase in LTC4 secretion caused by 0.1 µM
formyl-Met-Leu-Phe and 5 µg/ml cytochalasin B from 921 ± 238 to
3,067 ± 1,462 pg/106 eosinophils (P < 0.01).
Th1-Sup at the same dilution had no augmenting effect on stimulated
secretion of LTC4 in eosinophils despite substantial
concentrations of granulocyte-macrophage colony-stimulating factor
(GM-CSF) in the supernatant. Dilution of Th1-Sup caused increased
LTC4 that returned to baseline after immunoabsorption of
GM-CSF, suggesting the presence of a possible inhibitory factor. We
demonstrate that pretreatment of eosinophils with 1:5 dilution of
Th2-Sup but not of Th1-Sup causes substantial augmentation of
LTC4 secretion in vitro and establishes that human Th2
cells cause direct augmentation of LTC4 secretion within
15-30 min of exposure.
T helper cells; cytokine; T helper type 1-like cells; immunodepletion; leukotriene C4
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
THE INTERACTION BETWEEN Th2 cells and eosinophils is presumed to be a major mechanism in the pathogenesis of allergic inflammation (2-5, 11, 14, 29) and airway hyperresponsiveness (5, 8, 11, 28). These distinct subsets of CD4+ T helper (Th) cells, Th1 and Th2 phenotypes, have been defined in the murine system based on their cytokine secretion profiles after antigen stimulation (10, 27). In rodent models, Th2 cells have been shown to cause induction of airway hyperresponsiveness by a mechanism that is not replicated by murine Th1 cells. This induction of airway hyperresponsiveness in rodents also has been shown to be independent of interleukin (IL)-4 (3, 4). The same authors have shown that exposure to IL-5, a cytokine produced by Th2 but not by Th1 cells, for 24 h also causes increased expression of 5-lipoxygenase-activating protein and translocation of this enzyme to the nucleus (6). This was associated with an enhanced capacity for cysteinyl leukotriene synthesis after stimulation with calcium ionophore A-23187.
We have shown previously that short exposure (<30 min) of eosinophils to exogenous IL-5 causes cytosolic phospholipase A2 (cPLA2) phosphorylation but not translocation of cPLA2 to the nucleus (30). This short exposure was nonetheless associated with augmented production of leukotriene C4 (LTC4) after exogenous stimulation with formyl-Met-Leu-Phe, which caused translocation of cPLA2 to the nuclear membrane (24, 30, 31).
We hypothesized that these previously established interactions of exogenously administered cytokine could be replicated in vitro by short-term coincubation of supernatant from activated human Th2-like cells with freshly isolated human eosinophils. The objectives of this investigation were 1) to determine whether human Th2 cells interacted directly as activating or augmenting cells over the short time (<30 min) with human eosinophils in isolated cell systems (i.e., independently of other cells or mediators), 2) to determine whether stimulated Th2 (and Th1) cells secreted cytokines in concentrations sufficient to cause eosinophil secretion, and 3) to determine whether murine models of these interactions were relevant to human Th2 cell-eosinophil interactions.
As for rodents (10), similar distinctions in T cell populations have been established in human atopic subjects, and the Th2 cell has been implicated as the Th cell subtype predominantly involved in both atopy and human asthma (4, 14). However, CD4+ T cell populations consisting of Th1 and Th2 subsets are less explicitly defined in humans. There also has been no prior demonstration of direct stimulation of human eosinophils by Th2 cells in isolated systems.
Experiments thus were performed using cells isolated from human subjects and cultured in vitro. Using a technique previously developed in our laboratory for culture of Th1- and Th2-like cells derived from "naive" CD4+ T lymphocytes obtained from the peripheral blood of normal donors, we first examined the role of anti-CD3-stimulated human Th cell subtypes in causing augmented secretion of eosinophils. In further studies, we immunodepleted Th cytokines with specific monoclonal antibodies (MAbs) to determine their potential augmenting effects on eosinophil secretion. Our study is the first demonstration in vitro that there is a direct interaction between human Th2 (but not Th1)-like cells, causing substantial augmentation of stimulated eosinophil synthesis of cysteinyl leukotriene.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Isolation of Human Resting Naive CD4+ Th cells
Peripheral blood mononuclear cells were isolated from buffy coats of nonatopic donors (United Blood Services and Life-Source; Chicago, IL) by Ficoll gradient centrifugation. The naive CD4+ Th cells were purified by subjecting the treated cells to negative immunomagnetic selection as described previously (13, 22, 26).Generation of Human Th1- and Th2-Like Cells Derived From Naive CD4+ Th Cells
Purified naive CD4+ Th cells (106 cells) obtained from eight different donors were resuspended in RPMI 1640 medium supplemented with 10% fetal bovine serum, 20 mM glutamine, 100 IU/ml penicillin, and 100 µg/ml streptomycin and were transferred onto microplate wells coated overnight with 0.5 ml of 1 µg/ml humanized anti-CD3 MAb (OKT3 CDR) (1, 22). Irradiated (4,000 rad) 106 Epstein-Barr virus-transformed human B cells (JY-EBV cells) were added to wells containing naive CD4+ Th cells, as a source of accessory cells (25). The initial stimulation was performed by addition of the combination of exogenous recombinant human (rh) IL-1Preparation of Th Cell Supernatant for Incubation With Eosinophils
To determine the concentration of Th cell supernatant (Th-Sup) causing maximal augmentation of stimulated eosinophil secretion, serial dilutions of supernatants from activated Th1- and Th2-like cells (see above) were performed. Eosinophils were then pretreated with increasing dilutions of Th-Sup for 30 min at 37°C and activated with 0.1 µM formyl-Met-Leu-Phe plus 5 µg/ml cytochalasin B (fMLP/B) (15, 18, 20) for an additional 30 min. The perfusate then was assayed for LTC4 release (see below). These studies demonstrated that 1:5 dilution for Th2-Sup and 1:10 dilution for Th1-Sup were sufficient for substantial release of LTC4, and these concentrations were used in all subsequent studies (see below).Isolation of Human Peripheral Blood Eosinophils
Eosinophil purification was performed by a modification of the method of Hansel et al. (12). Peripheral blood (120 ml) was obtained from 21 mildly atopic donors in accordance with the approved institutional protocol. With this immunomagnetic separation technique, the purity of eosinophils was always >99% as confirmed by cell differential counting using Diff-Quik-stained cytoslides. The purified eosinophils were washed with Hanks' balanced salt solution (HBSS) before each experimental intervention. All experimental procedures were carried out on ice to prevent eosinophil activation. Viability was confirmed by using the trypan blue exclusion dye.Flow Cytometry
Two-color flow cytometry was used to assess the purity of the isolated naive human CD4+ T cells using the following MAbs: CD45RA-phycoerythrin (PE; clone B-C15, Biosource; Camarillo, CA); CD45RO-FITC (clone UCHL-1, Caltag; San Francisco, CA); and CD3-FITC and CD4-PE (Biosource) as described previously (22, 26). This method was used for all CD4+ T-cell isolations having mixed populations to discriminate clearly and to obtain discretely identifiable groups of positive cells, i.e., CD45RA.Sandwich ELISA
The concentrations of endogenously secreted cytokines from stimulated Th subsets were measured by sandwich ELISA (sELISA). MAb pairs (PharMingen; San Diego, CA) were utilized to quantify human IL-4, IL-5, IL-13, interferon-Enzyme Immunoassay
The concentration of LTC4 secreted during eosinophil activation was analyzed by competitive enzyme immunoassay (Cayman Chemical; Ann Arbor, MI) using a method that we have reported previously (16, 17, 19). The density measurements were made on a microplate absorbance spectrophotometer at 405 nm (Molecular Devices; Menlo Park, CA). The final concentrations were calculated from standard curves fitted by four-parameter analysis (Softmax v2.01 software, Molecular Devices), and data are expressed as picograms per million eosinophils (pg/106 eosinophils).Immunodepletion
Microplate wells were coated in duplicate with saturating concentrations (5 µg/ml) of MAbs directed against GM-CSF, IL-5, IL-13, or TNF-In separate studies (n = 4 undepleted Th1-Sup), microplate wells were coated with anti-GM-CSF as above, and undepleted Th1-Sup was pipetted onto the treated wells. Identical experiments were performed as for immunodepleted Th2-Sup. Because significant amounts of soluble GM-CSF were detected after stimulation from both Th1 and Th2 subsets, this experiment was conducted to determine whether GM-CSF secreted by activated Th1-like cells could cause augmented secretion of LTC4.
Experimental Interventions
Effect of Th1- and Th2-Sup on stimulated eosinophil secretion. Purified human eosinophils (2.5 × 105 eosinophils) from five different donors were resuspended in 100 µl of HBSS, pelleted by centrifugation and pretreated with either 200 µl of 1:5 dilution of 1) culture medium alone, 2) culture medium with rhIL-1/6/4, no Th2-Sup, 3) culture medium with rhIL-1/6/12, no Th1-Sup, 4) Th2-Sup alone, or 5) Th1-Sup alone for 30 min at 37°C. Eosinophils then were activated with 0.1 µM fMLP/B. Prior investigations have validated this method and concentration of fMLP/B, which causes metabolic burst activity (20), maximal secretion of eosinophil granular protein (19, 21), bronchoactive metabolites (17-19), and maximal eosinophil chemotaxis (15) without inducing cytoxicity (17-19). At the end of the incubation period, the reaction was terminated by centrifugation (Eppendorf 5415C, Brinkman Instrument; Westbury, NY) at 13,500 rpm for 2 min. The activated supernatant was saved for determination of LTC4 secretion (see above).Because 1:5 dilution of Th1-Sup had no augmentatory effect on stimulated eosinophil secretion of LTC4, serial dilutions of 1:10 and 1:25 were performed using Th1-Sup obtained from four donors. Experiments were performed in an identical manner as above, and the activated supernatant was saved for determination of LTC4 secretion (see above).
Effect of cytokine depletion from Th1- and Th2-Sup on stimulated eosinophil LTC4 secretion. Isolated eosinophils were pretreated for 30 min at 37°C with Th-Sup after depletion of secreted Th1- or Th2-like cell cytokines (see above and RESULTS). Experiments then were conducted in an identical manner as for either undepleted Th1- or Th2-Sup, and stimulated supernatant from the reaction tubes was collected for later analysis of LTC4 secretion (see above). As a control, eosinophils were exposed to isotype IgG-coated microplate wells and activated with either buffer control or fMLP/B for all groups (n = 8 eosinophil isolations).
Effect of exogenous recombinant human Th cytokines on stimulated
eosinophil LTC4 secretion. Isolated
eosinophils from four different donors were pretreated with exogenous
recombinant human cytokines, i.e., rhGM-CSF, rhIL-5, rhIFN-, and
rhTNF-
at concentrations similar to those of endogenously secreted
cytokines measured from CD3-stimulated Th-like cells. Activation was
elicited with either fMLP/B or buffer control as above, and the
supernatant from all experimental interventions was collected and
stored at
70°C until later analysis for LTC4 secretion.
Data Analysis
All data are expressed as the means ± SE. Final data analysis was performed using ANOVA to determine differences between cytokine depletion paradigms. As indicated by the F statistic for particular experimental interventions, collated data were analyzed further by Fisher's least protected difference test. When comparisons of paired data within a single experimental protocol were made, Bonferroni correction was applied after paired Student's t-test. Statistical significance was claimed at P < 0.05. ![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Validation and Viability of Isolated Naive CD4+ T Cells and Eosinophils
The isolation of mature, unstimulated naive Th cells derived from peripheral blood CD4+ T cells by immunomagnetic separation technique was reproducible in all cell preparations. Immunostaining of surface markers of the naive CD4+ T cells demonstrated >95% CD3+ CD4+ T cells. Staining for CD45RA (naive CD4+ T cells) and CD45RO (memory CD4+ T cells) showed no CD45RADifferentiation and Validation of Naive Th Subsets and Activation Markers
The differentiated cultured Th1- and Th2-like cells derived from naive CD4+ T cell-anti-CD3 MAb cross-linking revealed a similar pattern of cytokine production as previously reported (22, 26). In these differentiated cultured human CD4+ Th subsets, IL-5 was solely secreted by Th2-like cells, whereas IFN-Effect of 1:5 Dilution of Th1- and Th2-Sup on Stimulated Eosinophil Secretion
Activated secretion of LTC4 was augmented substantially only for eosinophils (n = 5 donors) pretreated with 1:5 dilution of Th2-Sup (Fig. 1). LTC4 secretion caused by fMLP/B activation was 921 ± 238 vs. 28.9 ± 9 pg/106 eosinophils for cells pretreated with buffer alone. There was no difference in stimulated secretion for eosinophils obtained from the same donors after pretreatment with 1:5 dilution of Th1-Sup (1,050 ± 319 pg/106 eosinophils, P = NS). However, exposure of eosinophils to 1:5 dilution of Th2-Sup caused a more than threefold augmentation of stimulated LTC4 secretion to 3,067 ± 1,462 pg/106 eosinophils (P < 0.01 vs. fMLP/B alone, no Th-Sup, or fMLP/B plus Th1-Sup; Fig. 1).
|
In separate studies using eosinophil aliquots from the same donors,
addition of culture medium containing either rhIL-1/6/12 used to
generate Th1-like cells or rhIL-1/6/4, which was used to generate
Th2-like cells, did not augment secretion of LTC4 in
activated human eosinophils in the absence of Th-Sup (P = NS for all comparisons vs. fMLP/B plus buffer control alone, no Th-Sup; Fig. 2).
|
Effect of Serial Dilution of Th1-Sup on Stimulated Eosinophil Secretion of LTC4
Because 1:5 dilution of Th1-Sup had neither a direct nor a priming effect on the stimulated eosinophil secretion (see Fig. 1), three different Th1-Sup were diluted 1:5, 1:10, and 1:25, and the effect on fMLP/B-induced LTC4 secretion was assessed (n = 4 eosinophil donors). Stimulated secretion of LTC4 was substantially decreased to 213 ± 53 pg/106 eosinophils for eosinophils treated with concentrated Th1-Sup vs. 982 ± 107 pg/106 eosinophils for buffer-treated eosinophils (P < 0.01; Fig. 3). Stimulated LTC4 secretion in eosinophils pretreated with 1:5 dilution of Th1-Sup was comparable to secretion from control (untreated) cells (1,096 ± 269 pg/106 eosinophils, P = NS). By contrast, a >1.8-fold increase to 1,813 ± 228 pg/106 eosinophils was obtained for stimulated eosinophils exposed to 1:10 dilution of Th1-Sup (P < 0.01 vs. 1:5 Th1-Sup and control). At 1:25 dilution there was no further effect on secretion of LTC4 caused by fMLP/B activation (P = NS vs. 1:10 Th1-Sup; Fig. 3).
|
Effect of Cytokine Depletion From Th1- and Th2-Sup on Stimulated Eosinophil LTC4 Secretion
The relative contribution of Th2 cytokines in augmenting eosinophil secretion caused by fMLP/B activation was assessed sequentially after immunodepletion in samples obtained from eight different donors. Depletion of GM-CSF by immunoabsorption caused a >40% decrease in LTC4 secretion caused by fMLP/B activation, to 1,832 ± 729 pg/106 eosinophils (P < 0.05 vs. undepleted Th2-Sup; Fig. 4). However, this level of stimulated secretion still was significantly greater than that obtained for eosinophils not exposed to Th2-Sup (921 ± 238 pg/106 eosinophils; P < 0.01). Pretreatment of eosinophils with IL-5-depleted Th2-Sup caused an even greater attenuation of fMLP/B-stimulated secretion, to 1,366 ± 614 pg/106 eosinophils [P < 0.001 vs. fMLP/B-activated Th2-Sup alone; P = NS vs. fMLP/B-stimulated cells not exposed to Th2-Sup (control); Fig. 4].
|
In contrast, depletion of IL-13 did not affect eosinophil secretion
caused by fMLP/B activation. For eosinophils treated with undepleted
Th2-Sup, fMLP/B-induced secretion of LTC4 was 3,027 ± 1,462 vs. 3,657 ± 2,237 pg/106 eosinophils
after IL-13 depletion. TNF--depleted Th2-Sup also had no effect in
LTC4 secretion (2,477 ± 1,056 pg/106
eosinophils; P = NS vs. undepleted Th2-Sup).
With use of an aliquot from the same eosinophil isolations,
LTC4 secretion caused by fMLP/B activation was 981 ± 107 vs. 8.6 ± 1.1 pg/106 eosinophils for control (IgG1
isotype plus buffer; P < 0.001; Fig.
5). For cells treated with undepleted 1:10
dilution of Th1-Sup, release of LTC4 increased
significantly to 1,818 ± 228 pg/106 eosinophils
(P < 0.05 vs. undepleted Th1-Sup plus fMLP/B). By contrast,
absorption of soluble GM-CSF from 1:10 dilution of Th1-Sup attenuated
the augmented LTC4 secretion caused by fMLP/B to near basal
level (Fig. 5).
|
Effect of Combined Immunodepletion of Th2-Sup Cytokines
Maximal inhibition of Th2-Sup augmentation of eosinophil secretion was achieved by depletion of IL-5 alone (see Fig. 4). Depletion of either IL-5 or GM-CSF caused a decrease in augmented eosinophil secretion by nearly threefold, and there was no further inhibition of augmented secretion by combined immunodepletion of both secretory IL-5 plus GM-CSF (Fig. 6). Interchanging the sequence of immunoabsorption, GM-CSF followed by IL-5, had no significant effect on LTC4 secretion (Fig. 6). Activated secretion of LTC4 was 1,318 ± 448 pg/106 eosinophils for eosinophils treated with Th2-Sup from which IL-5 was depleted (Fig. 5); this did not differ significantly for eosinophils treated with supernatant from which both GM-CSF and IL-5 were depleted (Fig. 6).
|
Effect of Exogenous Cytokines on Stimulated Eosinophils
To assess the effect of comparable concentrations of exogenously added cytokines on eosinophil secretion (n = 4 eosinophil isolations), further studies were generated in naive cells using concentrations measured in Th-Sup. At 5 ng/ml, rhGM-CSF-treated eosinophils caused a more than twofold increase in stimulated secretion of LTC4, from 920 ± 165 to 2,179 ± 19 pg/106 eosinophils (P < 0.01). Coincubation with 3 ng/ml rhIL-5 increased the stimulated synthesis of LTC4 to 1,632 ± 156 pg/106 eosinophils (P = NS vs. GM-CSF-treated cells; P < 0.05 vs. fMLP/B activated, no rh cytokines). Neither rhTNF-
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The objective of this investigation was to determine whether direct stimulation of Th cells caused eosinophil activation or augmentation of secretion of LTC4. Whereas many prior investigations have implicated the role of Th2 cells in initiating asthma and atopic responsiveness (5, 7, 9, 10, 28), there has been no prior report of direct interaction between Th cells and eosinophils in isolated cell systems. In these studies, we used a method to cause differentiation of CD3-stimulated peripheral human CD4+ lymphocytes into Th1- and Th2-like subsets (22). These cells demonstrated a clear pattern of cytokine secretion profiles, which indicated their similarity to Th cell subsets as differentiated in vivo (14, 23, 29). However, because IL-3 was not secreted by Th2-like subsets in this system, its relative activity in endogenous cell-cell interactions could not be assessed. A further hypothesis of this investigation was that secretion from the Th2 cell subset would cause substantially greater augmentation of eosinophil secretion than Th1 cells and that the difference could be related to the cytokine secretion profiles obtained in isolated cell systems in vitro.
Our data indicate that the supernatant from CD3-activated Th1-like cells had neither a direct stimulatory nor augmentatory effect on eosinophil secretion. However, supernatant from CD3-activated Th2-like cells caused a threefold augmentation of LTC4 release vs. sham control or medium containing rhIL-1/6/4 to cause differentiation of Th2 cells or rhIL-1/6/12 to generate Th1-like cells (Fig. 2). Accordingly, Th2 cells appear to lack the capacity to activate directly eosinophil secretion but have a unique capacity to augment the stimulated secretion of LTC4.
In further studies, we found that the augmentation of stimulated
secretion of eosinophils caused by pretreatment with Th2-Sup was
primarily related to secretion of IL-5 and secondarily to GM-CSF (Fig.
4). By contrast, a decrease in augmented eosinophil secretion caused by
CD3-stimulated Th2-like cells was not observed for eosinophils treated
with immunodepleted TNF- and/or IL-13. The system we used allowed us
to isolate the augmentatory stimulus. Th1- and Th2-like cells were
cultured de novo, and eosinophils were isolated from peripheral blood.
This allowed us to assess whether there was a direct interaction and
physiologically relevant relationship between Th-Sup priming of
eosinophil secretion for concentrations of cytokines generated from
CD3-stimulated Th cells. Although Th1- and Th2-like cells produced
similar quantities of soluble GM-CSF, our data indicate that secreted
cytokines from CD3-activated Th2-like cells are predominantly capable
of causing direct augmentation of human eosinophil secretion in the
absence of other intermediary cells or amplification responses.
It is important, however, to consider some limitations of our findings. The system we used to provide stimulus isolation in vitro involves a preparation of Th cells and eosinophils in an environment that may not replicate the in vivo situation in human asthma, and interactions with other cells and/or tissues cannot occur. However, the Th subsets that we used closely reflected the cytokine secretion profiles of Th1- and Th2-like cells from both mouse (3, 4, 8, 27) and human systems (14, 22, 26). Furthermore, specific interactions that occur solely between Th cells and eosinophils cannot be assessed accurately in the presence of other inflammatory cells or matrix (2, 21). Another unanswered question is why GM-CSF, which was secreted in comparable quantities from both Th1- and Th2-like cells, caused apparent augmentation of eosinophil secretion only for eosinophils treated with Th2 cell supernatant. rhGM-CSF substantially augments eosinophil secretion when given exogenously in the absence of Th cells (16). Prior investigations in rodents have indicated that augmented airway responsiveness is elicited only by Th2 cells and not by Th1 cells (3, 4). This increase in airway hyperresponsiveness was shown to be independent of IL-4, but no mechanism for the selective augmentation of airway hyperresponsiveness by Th2 cells vs. Th1 cells in mice was elucidated.
In this study, we observed an inhibitory effect in Th1-Sup that could account for Th2 selectivity in augmenting eosinophil secretion. Although we were unable to identify the soluble factor(s) associated with apparent Th1-Sup inhibition of stimulated eosinophil secretion, we demonstrated a substantial increase in LTC4 secretion by serial dilution of Th1-Sup (Fig. 3). We further investigated whether exogenous application of cytokines secreted by either activated Th1- or Th2-like cells could mimic the augmenting effect on eosinophil secretion observed in Th2-Sup-treated eosinophils. Pretreatment of naive eosinophils with either rhGM-CSF or rhIL-5 in concentrations determined from Th-Sup caused comparable augmentation of LTC4 secretion (Figs. 4 and 7). Other endogenously secreted cytokines from Th subsets did not affect the synthesis of cysteinyl leukotrienes when added exogenously to naive eosinophils (Fig. 7).
Although our data establish a likely role for direct Th2-Sup augmentation of stimulated de novo LTC4 synthesis in eosinophils, we did not identify a physiological trigger for eosinophil activation. The secretory stimulus hence was modeled for control and Th cell supernatant exposure by activation of eosinophils with fMLP/B. This method is well established (17-20), and augmentation of fMLP/B-induced secretion did not occur in control studies after exposure to cytokines, causing Th subset differentiation, or for CD3-stimulated Th1 cells. Hence, secretion caused by fMLP/B reflects cellular synthesis of LTC4 (15, 17-19, 21), and controls were obtained to validate conditions for these specific experiments. Whereas these data did not establish the Th2-like cell as the cell causing direct activation of eosinophil secretion (as contrasted to augmentation of secretion), our data do not exclude the possibility that Th2 cells could trigger eosinophil secretion as well under more physiological circumstances. Although the mechanism by which augmented secretion was elicited by IL-5 and GM-CSF was not examined directly in this study, we have shown previously that rhIL-5 caused increased phosphorylation of cPLA2, the enzyme that hydrolyzes the nuclear membrane phospholipids causing arachidonic acid release, which is the initial step in the synthesis of cysteinyl leukotrienes (24, 30, 31). Because phosphorylation (30) and augmented secretion of LTC4 occur within 30 min (24) after cell activation, we did not examine the effects of this short incubation time on mRNA expression of enzymes in the 5-lipoxygenase pathway.
We conclude that at a physiological concentration of secretion, supernatant (1:5 dilution) from cultured human Th2-like cells, but not from human Th1-like cells, is capable of substantially augmenting the synthesis of LTC4 in isolated, pharmacologically stimulated human eosinophils. This augmentation results predominantly from secretion of IL-5, solely secreted by CD3-activated Th2-like cells, and GM-CSF, a cytokine commonly secreted from both Th subsets.
![]() |
ACKNOWLEDGEMENTS |
---|
This work was supported by National Heart, Lung, and Blood Institute Grant HL-46368, Specialized Center of Research Grant HL-56399, National Institute of Allergy and Infectious Diseases Grant 2PO1-AI-20531-06, and by a grant from Glaxo Wellcome.
![]() |
FOOTNOTES |
---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: A. R. Leff, Section of Pulmonary and Critical Care Medicine, Dept. of Medicine M6076, Univ. of Chicago, 5841 S. Maryland Ave., Chicago, IL 60637 (E-mail: aleff{at}medicine.bsd.uchicago.edu).
Received 1 July 1999; accepted in final form 11 January 2000.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Alegre, M,
Collins AM,
Pulito VL,
Brosius RA,
Olsen WC,
Zivin RA,
Knowles R,
Thistlewaite JR,
Jolliffe LK,
and
Bluestone JA.
Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody.
J Immunol
148:
3461-3468,
1992
2.
Coffer, PJ,
Schweizer RC,
Dubois GR,
Maikoe T,
Lammers JW,
and
Koenderman L.
Analysis of signal transduction pathway in human eosinophils activated by chemoattractants and the T-helper-2-derived cytokines interleukin-4 and interleukin-5.
Blood
91:
2547-2557,
1998
3.
Cohn, L,
Homer RJ,
Macleod H,
Mojrs M,
Brombacher F,
and
Bottomly K.
Th2-induced airway mucus production is dependent on ILI-4Ra, but not on eosinophils.
J Immunol
162:
6178-6183,
1999
4.
Cohn, L,
Tepper JS,
and
Bottomly K.
IL-4-independent induction of airway hyperresponsiveness by Th2- but not Th1-cells.
J Immunol
161:
3813-3816,
1998
5.
Corrigan, CJ,
and
Kay AB.
T-cell/eosinophil interactions in the induction of asthma.
Eur Respir J Suppl
22:
72s-78s,
1996[Medline].
6.
Cowburn, AS,
Holgate ST,
and
Sampson AP.
IL-5 increases expression of 5-lipoxygenase activating protein and translocates 5-lipoxygenase to the nucleus in human blood eosinophils.
J Immunol
163:
456-465,
1999
7.
Del Prete, GF,
de Carli M,
D'Elios MM,
Masetrelli P,
Ricci M,
Fabbri L,
and
Romagnani S.
Allergen exposure induces the activation of allergen specific Th2 cells in the airway mucosa of patients with allergic respiratory disorders.
Eur J Immunol
23:
1445-1449,
1996.
8.
Ewart, SL,
Gavett SH,
Margolick J,
and
Willis-Karp M.
Cyclosporin A attenuates genetic airway hyperresponsiveness in mice but not through inhibition of CD4+ and CD8+ T cells.
Am J Respir Cell Mol Biol
14:
627-634,
1993[Abstract].
9.
Fukuda, T,
Asakawa J,
Motojima S,
and
Makino S.
Cyclosporine A reduces T lymphocyte activity and improves airway hyperresponsiveness in corticosteroid-dependent chronic severe asthma.
Ann Allergy Asthma Immunol
75:
65-72,
1995[ISI][Medline].
10.
Gajewski, TF,
Pinnes M,
Wong T,
and
Fitch FW.
Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations.
J Immunol
146:
1750-1758,
1991
11.
Gerblich, AA,
Salik H,
and
Schuyler MR.
Dynamic T cell changes in peripheral blood and bronchoalveolar lavage after antigen provocation in asthmatics.
Am Rev Respir Dis
143:
533-537,
1991[ISI][Medline].
12.
Hansel, TT,
deVries JM,
Iff T,
Rihs S,
Wandzilak M,
Betz S,
Blaser K,
and
Walker C.
An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils.
J Immunol Methods
145:
105-110,
1991[ISI][Medline].
13.
Horgan, KJ,
and
Shaw S.
Immunomagnetic purification of T cell subpopulations.
In: Current Protocols in Immunology, edited by Coligan JE,
Kruisbeck AM,
Margulies DH,
Shevach EM,
and Strober W.. New York: Wiley Interscience, 1991, vol. 1, p. 7.4.1-7.4.5.
14.
Kon, OM,
and
Kay AB.
T cells and chronic asthma.
Int Arch Allergy Immunol
118:
133-135,
1999[ISI][Medline].
15.
Muñoz, NM,
Douglas I,
Mayer D,
Herrnreiter A,
Zhu X,
and
Leff AR.
Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism.
Am J Respir Crit Care Med
155:
1398-1403,
1997[Abstract].
16.
Muñoz, NM,
Mayer D,
McAllister K,
and
Leff AR.
Enhancement of eosinophil function by GM-CSF and blockade by beta-adrenergic agonists (Abstract).
Am Rev Respir Dis
149:
A836,
1994.
17.
Muñoz, NM,
Rabe KF,
Neeley SP,
Herrnreiter A,
Zhu X,
McAllister K,
Mayer D,
Magnussen H,
Galens S,
and
Leff AR.
Eosinophil VLA-4 binding to fibronection augments bronchial narrowing through 5-lipoxygenase activation.
Am J Physiol Lung Cell Mol Physiol
270:
L587-L594,
1996
18.
Muñoz, NM,
Rabe KF,
Vita AJ,
McAllister K,
Mayer D,
Weiss M,
and
Leff AR.
Paradoxical blockade of beta adrenergically mediated inhibition of stimulated eosinophil secretion by salmeterol.
J Pharmacol Exp Ther
273:
850-854,
1995[Abstract].
19.
Muñoz, NM,
Vita AJ,
Neeley SP,
McAllister K,
Spaethe SM,
White SR,
and
Leff AR.
Beta-adrenergic modulation of formyl-methionine-leucine-phenylalanine-stimulated secretion of eosinophil peroxidase and leukotriene C4.
J Pharmacol Exp Ther
268:
139-143,
1994[Abstract].
20.
Nagata, M,
Sedgwick JB,
and
Busse WW.
Differential effects of granulocyte-macrophage colony-stimulating factor on eosinophil and neutrophil superoxide anion generation.
J Immunol
155:
4948-4954,
1995[Abstract].
21.
Neeley, SP,
Hamann KJ,
Dowling T,
McAllister K,
White S,
and
Leff AR.
Augmentation of stimulated eosinophil degranulation by VLA-4 (CD49d)-mediated adhesion to fibronectin.
Am J Respir Cell Mol Biol
11:
206-213,
1994[Abstract].
22.
Palmer, EM,
and
van Seventer GA.
Human T helper cell differentiation is regulated by the combined action of cytokines and accessory-cell dependent costimulatory signals.
J Immunol
158:
2654-2662,
1997[Abstract].
23.
Paul, WE,
and
Seder RA.
Lymphocyte responses and cytokines.
Cell
76:
241-251,
1994[ISI][Medline].
24.
Sano, A,
Muñoz NM,
Sano H,
Choi J,
Zhu X,
Jacobs B,
and
Leff AR.
Inhibition of cPLA2 translocation and leukotriene C4 secretion by fluticasone propionate in exogenously activated human eosinophils.
Am J Respir Crit Care Med
159:
1903-1909,
1999
25.
Seder, RA,
and
Paul WE.
Acquisition of lymphokines-producing phenotype by CD4+ T cells.
Annu Rev Immunol
12:
635-673,
1994[ISI][Medline].
26.
Semnani, RT,
Szoboda K,
Khoshnood B,
and
van Seventer GA.
A question of interleukin-5 secretion by human naïve T-helper cells is regulated by distinct signal from both the T-cell receptor/CD3 complex and CD2.
Scand J Immunol
47:
436-443,
1998[ISI][Medline].
27.
Street, NE,
Schumacher JH,
Fong T,
Bass H,
Florentino DF,
Leverah JA,
and
Mosmann TR.
Heterogeneity of mouse helper T cells: evidence from bulk cultures and limiting dilutions cloning for precursors of Th1 and Th2 cells.
J Immunol
144:
1629-1639,
1990
28.
Virchow, JC,
Oehling A,
Boer L,
Hansel TT,
Werner P,
Mathys H,
Blaser K,
and
Walker C.
Pulmonary function, activated T cells, peripheral blood eosinophilia, and serum activity for eosinophil survival in vitro. A longitudinal study in bronchial asthma.
J Allergy Clin Immunol
94:
240-249,
1994[ISI][Medline].
29.
Wierenga, EA,
Snoek M,
de Groot C,
Chretien I,
Bos JD,
Jansen HM,
and
Kaspenberg ML.
Evidence for compartmentalization of junctional subsets of CD4+ T lymphocytes in atopic patients.
J Immunol
144:
4651-4656,
1990
30.
Zhu, X,
Muñoz NM,
Kim KP,
Sano H,
Cho W,
and
Leff AR.
Cytosolic phospholipase A2 activation is essential for 1 and
2 integrin-dependent adhesion of human eosinophils.
J Immunol
163:
3423-3429,
1999
31.
Zhu, X,
Muñoz NM,
Kim KP,
Sano H,
Choi J,
and
Leff AR.
Cytosolic phospholipase A2 is phosphorylated during IL-5 priming of human eosinophils (Abstract).
Am J Respir Crit Care Med
159:
A94,
1999[ISI].